Merrion Holds on U.S. Offering

Merrion Pharmaceutical has postponed the U.S. leg of its initial public offering following the squeeze in capital markets that is due to the credit crunch, but the drug company went ahead with its 2 million share placement on Dublin's IEX.  According to Irish Independent, Merrion's shares were priced at